Mesenchymal stromal cells
[대역어] 중간 엽 기질 세포
[용어속성] Term
[용어속성] Term
The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
코로나19 환자를 위한 중간엽 기질세포의 임상적 효능 및 안전성: 무작위 대조 시험의 체계적인 검토 및 메타 분석
Meta-Analysis
[키워드] 28-day mortality
95% CI
addition
adverse event
adverse events
AEs
appear
Clinical efficacy
Clinical improvement
Clinical outcome
clinical outcomes
ClinicalTrials
Cochrane Library
control group
controls
COVID-19
help
IMPROVE
investigated
Mesenchymal stromal cell
Mesenchymal stromal cells
Meta-analysis
Mortality
mortality rate
MSC
MSCs
OVID
Patient
patients
patients with COVID-19
Placebo
placebos
Randomized controlled trial
Randomized controlled trials
RCT
RCTs
risk
Safe
SARS-CoV-2
searched
serious AE
serious AEs
significantly higher
significantly lower
stromal cell
stromal cells
systematic review
therapeutic option
treat
Treatment
[DOI] 10.1016/j.jiph.2022.07.001 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1016/j.jiph.2022.07.001 PMC 바로가기 [Article Type] Meta-Analysis
Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
SARS-CoV-2 감염의 치료 및 예방을 위한 세포 요법
Article
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
addition
Antiviral
Blood
blood disorders
cells
cellular immunity
Cellular therapies
cellular therapy
coronavirus
described
disorder
Efficacy
feasibility
immune
immune modulation
include
increased risk
Infection
Mesenchymal stromal cells
modulating
natural killer cell
Natural killer cells
PROTECT
Regulatory T cell
regulatory T cells
Respiratory disease
SARS-COV-2 infection
severe acute respiratory syndrome Coronavirus
severe respiratory disease
stromal cells
suppressed
T cells
therapy
Treatment
Trial
viral shedding
virus-specific T cell
vulnerable patient
[DOI] 10.1182/blood.2021012249 PMC 바로가기 [Article Type] Article
[DOI] 10.1182/blood.2021012249 PMC 바로가기 [Article Type] Article
Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval
COVID-19를 치료하기 위한 중간엽 간질 세포의 통제된 시험에 대한 업데이트된 살아있는 체계적인 검토 및 메타 분석: 신속한 승인-빠른 승인을 위한 시험 증거의 가속화된 합성을 위한 프레임워크
Meta-Analysis
[키워드] accelerate
accelerated
acute respiratory distress
acute respiratory distress syndrome
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
appear
approval
ARDS
Clinical studies
clinical study
conducted
Consistency
Control
Controlled
controls
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
criteria
Critical
death
Endpoint
evaluate
Evidence
Exosomes
Extracellular
Extracellular vesicles
facilitate
framework
heterogeneity
Hospital stay
identify
IMPROVE
ISCT
Master protocol
mean difference
Mesenchymal stem cells
Mesenchymal stromal cell
Mesenchymal stromal cells
Meta-analysis
Microvesicles
moderate
Mortality
MSC
MSC-EVs exosomes
MSCs
non-randomized study
outcome
Oxygenation
Patient
Pneumonia
PROSPERO
protocol
random-effect
random-effects
Random-effects meta-analysis
Randomized controlled trial
Rapid
reduce
reduce mortality
Relative risk
reported
respiratory distress
Respiratory distress syndrome
review
risk of bia
risk of death
RoB
SARS-CoV-2
Sepsis
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
Society
stromal cell
stromal cells
synthesis
systematic review
treat
Treatment
[DOI] 10.1093/stcltm/szac038 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1093/stcltm/szac038 PMC 바로가기 [Article Type] Meta-Analysis
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial
Clinical Trial
[키워드] acute respiratory distress
acute respiratory distress syndrome
adverse effect
ARDS
bone
Bone marrow
cells
cellular
cellular therapy
clinical
Cohort
control patient
control patients
COVID-19
COVID-19 disease
Critical
D-dimer value
Dexamethasone
Efficacy
Endocarditis
evaluate
extracorporeal membrane oxygenation
group
high mortality
High-flow nasal oxygen
Immune cell
Immune-mediated
induce
Inflammation
Inflammatory response
intensive care
intensive care unit (ICU)
interval
intravenous infusion
invasive
Invasive mechanical ventilation
limit
mechanical ventilation
median
Mesenchymal stromal cells
MSC
MSC-treated
MSCs
nasal
no significant difference
observation
outcome
oxygen
Patient
patients
phase
phenotype
Randomized controlled trial
Regulatory
reported
required
requiring supplemental oxygen
Result
Safe
SARS-CoV-2
severe COVID-19
significantly higher
significantly lower
Statistical tests
stimulate
stroke
stromal cell
survival
syndrome
therapy
tissue repair
treated
Trial
[DOI] 10.3389/fimmu.2022.932360 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.3389/fimmu.2022.932360 PMC 바로가기 [Article Type] Clinical Trial
Clinical progress in MSC-based therapies for the management of severe COVID-19
Mini review
[키워드] MB-MSCs
Menstrual blood-derived Mesenchymal Stromal Cells
3-dioxygenase
ACE2angiotensin converting enzyme 2
acute graft-versus-host disease
acute respiratory distress syndrome
Adipose Tissue derived Mesenchymal Stromal Cells
admadministration
administration
alanine aminotransferase
Allo-MSCsAllogeneic Mesenchymal Stromal Cells
Alloallogeneic
Allogeneic
Allogeneic Mesenchymal Stromal Cells
ALTalanine aminotransferase
angiotensin converting enzyme 2
anti-inflammatory property
ARDS
ARDSacute respiratory distress syndrome
Aspartate aminotransferase
ASTaspartate aminotransferase
AT-MSCsAdipose Tissue derived Mesenchymal Stromal Cells
AT2type 2 alveolar cells of the lungs
BALFbronchoalveolar lavage fluid
BM-MSCsbone marrow derived MSCs
body weight
bone marrow derived MSCs
Bronchoalveolar lavage fluid
bwBody weight
C-reactive protein
cAMPcyclic adenosine monophosphate
candidate
CDcluster of differentiation
Cell
clinical
clinical trial
cluster of differentiation
complex
conducted
Coronavirus disease 2019
coronavirus disease of 2019
COVID-19
COVID-19Coronavirus disease of 2019
CRPC-reactive protein
cyclic adenosine monophosphate
cytokine
Daewoong Pharmaceutical’s Mesenchymal Stromal Cells
DCsdendritic cells
dendritic cells
driven by
DSCsPlacenta-derived decidua stromal cells
DW-MSCsDaewoong Pharmaceutical’s Mesenchymal Stromal Cells
EVsextracellular vesicles
Extracellular vesicles
Fas ligands
Fas-LFas ligands
FDAFood and Drug Administration
FGFfibroblast growth factor
fibroblast growth factor
Food and Drug Administration
forkhead box P3 +
FOXP3 +forkhead box P3 +
G-CSFgranulocyte colony-stimulating factor
Gal-1galectin-1
Gal-3galectin-3
Gal-9galectin-9
galectin-1
galectin-3
Galectin-9
GM-CSFgranulocyte macrophage-colony stimulating factor
granulocyte colony-stimulating factor
granulocyte macrophage-colony stimulating factor
growth factor
GvHDacute graft-versus-host disease
HB-AT-MSCsHope Biosciences autologous adipose-derived mesenchymal stromal cells
HdHigh dose
hepatocyte growth factor
HGFhepatocyte growth factor
High dose
HLAHuman leukocyte antigen
Hope Biosciences autologous adipose-derived mesenchymal stromal cells
human leukocyte antigen
ICUIntensive Care Unit
IDOIndoleamine 2
IFN-γinterferon-γ
IL-10interleukin-10
IL-1interleukin-1
IL-1βinterleukin-1β
IL-2 receptor
IL-2interleukin-2
IL-2RIL-2 receptor
IL-4interleukin-4
IL-6interleukin-6
IL-7Interleukin 7
IL-7interleukin-7
IL-8interleukin 8
IL-9interleukin
IL1-αinterleukin 1-α
IL1-βinterleukin 1-β
IL1RaInterleukin-1 receptor antagonist
immune dysregulation
immunological
immunomodulatory
IMVInvasive mechanical ventilation
Indoleamine 2
inducible protein 10
inflammatory process
inhalation
INHinhalation
intensive care unit
interferon-γ
interleukin
interleukin 1-α
interleukin 1-β
Interleukin 7
interleukin 8
interleukin-1
Interleukin-1 receptor antagonist
interleukin-10
interleukin-1β
interleukin-2
Interleukin-4
interleukin-6
interleukin-7
intravenous
Invasive mechanical ventilation
IP-10inducible protein 10
IVintravenous
keratinocyte growth factor
KGFkeratinocyte growth factor
lactate dehydrogenase
LDHlactate dehydrogenase
LdLow dose
lipopolysaccharide
low dose
LPSlipopolysaccharide
major histocompatibility complex
management
MAPKmitogen-activated protein kinase
MCP-1monocyte chemoattractant protein-1
Mesenchymal stromal cell
Mesenchymal stromal cells
MHCMajor Histocompatibility Complex
microRNA
miRNAmicroRNA
MIS-Cmultisystem inflammatory syndrome in children
mitogen-activated protein kinase
monocyte chemoattractant protein-1
MSCs
MSCsmesenchymal stromal cells
multisystem inflammatory syndrome in children
nanovesicles
National Institutes of Health
natural
NETsNeutrophil Extracellular Traps
Neutrophil extracellular traps
NF-κBnuclear factor-kappa B
NIHNational Institutes of Health
nitric oxide
NKnatural
NONitric Oxide
nuclear factor-kappa B
NVsnanovesicles
occur
PD-1programmed cell death protein 1
PD-L1programmed death ligand-1
PGE2prostaglandin E2
pharmacological management
PL-MSCsPlacental-derived Mesenchymal Stromal Cells
Placenta-derived decidua stromal cells
placental expanded
Placental-derived Mesenchymal Stromal Cells
PLX-PADplacental expanded
programmed cell death protein 1
programmed death ligand-1
prostaglandin E2
protein spike
public health
reactive oxygen species
Regulatory T cell
Respiratory failure
RFrespiratory failure
ROSreactive oxygen species
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
Secretome
severe acute respiratory syndrome coronavirus 2
severe COVID-19
Severe respiratory distress
signal transducer activators of transcription-3
Sprotein spike
STAT3signal transducer activators of transcription-3
syndrome
TGF-β1transforming growth factor-β1
TGFtransforming growth factor
the cytokine storm
the disease
therapeutic
therapy
TLRtoll-like receptors
TNF-α-stimulating gene 6
TNF-αtumor necrosis factor-α
TNFTumor Necrosis Factor
Toll-like receptors
transforming growth factor
transforming growth factor-β1
treat
Tregregulatory T cell
TSG-6TNF-α-stimulating gene 6
tumor necrosis factor
tumor necrosis factor-α
type 2 alveolar cells of the lungs
UC-MSCsumbilical cord derived MSCs
umbilical cord derived MSCs
vascular endothelial growth factor
VEGFvascular endothelial growth factor
Wharton’s Jelly–derived Mesenchymal Stromal Cells
WJ-MSCsWharton’s Jelly–derived Mesenchymal Stromal Cells
[DOI] 10.1016/j.cytogfr.2022.07.002 [Article Type] Mini review
[DOI] 10.1016/j.cytogfr.2022.07.002 [Article Type] Mini review
Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial
Clinical Trial
[키워드] acute respiratory distress syndrome
addition
adverse effect
approach
ARDS
ARDS patient
ARDS patients
Cell
change
clinical
clinical trial
control group
correlated
COVID-19 pandemic
COVID-19 patient
CRP level
CT scan
Cytokine storm
demonstrated
disease
distress
Features
follow-up period
functions
IFN-g
IL-10
IL-17
IL-1B
IL-6
Inflammatory cytokines
injection
Intervention
intervention group
intravenous
intravenous infusion
Mesenchymal stromal cells
Mild-to-moderate
MSC
MSCs
Open-label
Patient
Registered
registry
required
respiratory
Safe
Safety
Sample size
serum CRP
serum cytokine
serum cytokine level
significant decrease
significant increase
single-center
SPO
standard care
stromal cell
study period
syndrome
therapy
TNF-α
UC-MSC
UC-MSCs
umbilical
were assessed
[DOI] 10.1186/s13287-022-02920-1 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1186/s13287-022-02920-1 PMC 바로가기 [Article Type] Clinical Trial
Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19
COVID-19에 대한 중간엽 줄기/기질 세포 기반 치료법: 살아있는 체계적인 검토 및 메타 분석의 첫 번째 반복: MSC 및 COVID-19
Meta-Analysis
[키워드] 95% CI
95% confidence interval
acute respiratory distress
acute respiratory distress syndrome
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
adherence
adverse effects
Analysis
appear
case sery
Cell
Cell-based therapy
Clinical outcome
Control
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
criteria
Critical
determine
Efficacy
Endpoint
estimate
Exosomes
Extracellular
Extracellular vesicles
Follow-up
Future
heterogeneity
immunomodulatory
interleukin-6
ISCT
iteration
Mesenchymal stem cells
Mesenchymal stromal cells
Meta-analysis
Microvesicles
moderate
Mortality
MSC
MSCs
nine
not performed
Other outcome
Other outcomes
pandemic
patients
patients with COVID-19
performed
Pneumonia
potential risk
primary analysis
random-effect
random-effects
repeated
reported
respiratory distress
Respiratory distress syndrome
risk
risk of bia
risk of death
risk ratio
RoB
SARS-CoV-2
Secondary outcomes
secreted
Sepsis
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
standardized mean difference
Statistical power
stromal cells
Study design
systematic review
therapy for COVID-19
tissue repair
treat
[DOI] 10.1016/j.jcyt.2021.12.001 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1016/j.jcyt.2021.12.001 PMC 바로가기 [Article Type] Meta-Analysis
Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial
간질 세포 투여에 의한 급성 호흡 곤란 증후군의 회복(REALIST): 공개 라벨 용량 증량 1상 시험에 이어 무작위, 삼중 맹검, 할당 은폐, 위약 대조 2상 시험을 위한 구조화된 연구 프로토콜
Article
[키워드] 1:1
acute respiratory distress
acute respiratory distress syndrome
administration
allocation
ARDS
benefit
blind
causes
Cell
cells
clinical
clinical trial
Cohort
cohort of patient
cohorts of patients
concealed
CONSORT
COVID-19
distress
dose
dose-escalation
early stage
early stages
Efficacy
EudraCT
Good
immunomodulatory
incidence
include
Mesenchymal stem cells
Mesenchymal stromal cell
Mesenchymal stromal cells
moderate to severe
MSC
MSCs
multicentre
NHS
number
Open-label
outcome
outlined
oxygenation index
patients
patients with moderate
Phase 1
phase 1 trial
Phase 2
phase 2 trial
Placebo
placebo-controlled
placebo-controlled trial
Practice
produced
protocol
randomised
rationale
receive
recruited
recruitment
repair
reported
Reporting
respiratory distress
Respiratory distress syndrome
Serious Adverse Events
severe ARDS
Standard
stromal cell
stromal cells
Study protocol
syndrome
therapy
Trial
triple-blind
umbilical
Umbilical cord
[DOI] 10.1186/s13063-022-06220-0 PMC 바로가기 [Article Type] Article
[DOI] 10.1186/s13063-022-06220-0 PMC 바로가기 [Article Type] Article
Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial
Clinical Trial
[키워드] acute COVID-19
biochemical
Blood
caused
cell subpopulation
Cell therapy
clinical
clinician
complex
consequence
COVID-19
COVID-19 patients
Critically ill
CT scan
cytokine
D-dimer
decrease
diagnosed with COVID-19
disease
disorder
dose
dosing interval
double-blind
early stages
Efficacy
extension
ferritin
Follow-up
IL-6
immune dysregulation
immunomodulatory property
increase in
Inflammatory
intensive care
intravenous dose
invasive mechanical
knowledge
Laboratory testing
lung damage
lymphocyte
Mesenchymal stromal cell
Mesenchymal stromal cells
MSC
MSCs
neutrophil
organ
parameter
PASC
Patient
Placebo
placebo-controlled clinical trial
Postacute sequelae.
Prevent
Randomized
randomized clinical trial
reactive
reduction
reduction in
Registered
registry
Safe
Safety
SARS-CoV-2
Severe case
severe complication
single-center
stromal cell
Surveillance
Symptom
Symptoms
TCD4
therapy
tissue damage
tissue injury
Treatment
UC-MSC
UC-MSCs
umbilical
Viral load
with COVID-19
[DOI] 10.1186/s13287-022-02796-1 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1186/s13287-022-02796-1 PMC 바로가기 [Article Type] Clinical Trial